Bullfrog AI Holdings Inc. (BFRG)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Bullfrog AI stock offers a rare opportunity for investors to take profit
Bullfrog AI Inc more than doubled on Mar. 30 after announcing a landmark commercial agreement with a “top 5” pharma leader to identify novel therapeutic targets for Major Depressive Disorder. In its press release, BFRG said the pharmaceutical giant has agreed to use its proprietary bfLEAP® platform – providing high-profile validation of its machine-leaning-driven drug discovery tech.
Top 4 Health Care Stocks That May Keep You Up At Night
As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Bullfrog AI Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SAS Stephane Astruc/ Salomon Sebban J. Safra Sarasin Holding AG | 113,720 | $191,050 | $77,898.2 | -$113,151.8 | -59.23% |
 Courtney Haddad Concurrent Investment Advisors, LLC | 10,000 | $16,800 | $6,559 | -$10,241 | -60.96% |
 Matthew Riley Hickory Point Bank & Trust | 2,000 | $3,360 | $1,290.8 | -$2,069.2 | -61.58% |
Bullfrog AI Holdings Inc. (BFRG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bullfrog AI Holdings Inc. ever had a stock split?
Bullfrog AI Holdings Inc. Profile
| Technology Hardware, Storage & Peripherals Industry | Information Technology Sector | Vininder Singh CEO | NASDAQ (CM) Exchange | 12021E109 CUSIP |
| US Country | 9 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Bullfrog AI Holdings, Inc. is a pioneering digital biopharmaceutical entity entrenched in the advancement of artificial intelligence (AI) and machine learning (ML) for the purpose of delving into diverse data sets across medicine and healthcare sectors within the United States. This innovative company distinguishes itself by leveraging cutting-edge AI/ML technologies to decipher complex clinical and preclinical data, aiming to streamline and enhance the development process of medical treatments and healthcare solutions. Founded in 2017 and headquartered in Gaithersburg, Maryland, Bullfrog AI Holdings, Inc. stands at the forefront of technological integration into biopharmaceutical research and development, promising to unlock new horizons in the fight against various diseases and health conditions.
Products and Services
- bfLEAP
- Licensing Agreements
- siRNA targeting Beta2-spectrin granted by George Washington University, focuses on the treatment of human diseases like hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
- A formulation of Mebendazole obtained from Johns Hopkins University, aimed at the treatment of glioblastoma, and various human cancer or neoplastic diseases.
An advanced analytical AI/ML platform developed by Bullfrog AI Holdings, Inc., bfLEAP signifies a leap forward in the analysis of preclinical and/or clinical data. This platform is specifically designed to sift through vast datasets, identifying patterns and insights that can accelerate drug development processes, improve diagnosis, and tailor more effective treatment plans. By harnessing the power of bfLEAP, researchers and healthcare professionals can navigate the complexities of medical data more efficiently, paving the way for significant breakthroughs in medicine.
Bullfrog AI Holdings, Inc. has established notable licensing agreements with prestigious institutions such as George Washington University and Johns Hopkins University. These partnerships facilitate the utilization of cutting-edge treatments and formulations in tackling critical health issues:
These collaborations not only extend the company's research capabilities but also underscore its commitment to developing innovative healthcare solutions that can make a difference in patients' lives.
